Difference between revisions of "Team:Freiburg/Parts"
m |
(new version) |
||
Line 31: | Line 31: | ||
Bitte auf Artnamen achten (Vorname Groß, Nachname klein, alles kursiv (Philipp)) Bezüglich pop: warum ist pSB1C3 ein doofes Backbone für die expression? warum wird iGEM viel mehr proteinexpression machen (in-vitro ist en vogue)? Warum habt ihr plötzlich angefangen ein anderes Backbone genutzt? (Resistenz, lacI etc). Kurz: Warum ist pOP cool? | Bitte auf Artnamen achten (Vorname Groß, Nachname klein, alles kursiv (Philipp)) Bezüglich pop: warum ist pSB1C3 ein doofes Backbone für die expression? warum wird iGEM viel mehr proteinexpression machen (in-vitro ist en vogue)? Warum habt ihr plötzlich angefangen ein anderes Backbone genutzt? (Resistenz, lacI etc). Kurz: Warum ist pOP cool? | ||
</br> neuer Versuch (9.9.15 Lara) | </br> neuer Versuch (9.9.15 Lara) | ||
+ | </br> Ramona: Hab nochmal etwas umgebaut. Denke, der pOP kommt jetzt besser raus, die Details dazu findet man aber nach wie vor auf seiner eigenen Seite, die jetzt allerdings auch direkt im Text verlinkt ist. | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
− | |||
+ | <p> | ||
+ | Our project involved the expression of many antigenic peptides. Their immunodominant properties make them feasible for many medical purposes. As ‘Health and Medicine’ is one of the most popular tracks chosen by iGEM teams, we want to share the sequences encoding for these peptides with the iGEM community. Thus, future iGEM teams have the opportunity to take advantage from our research if they are planning to work in the field of diagnostics. | ||
</br> | </br> | ||
+ | Most of the sequences were obtained by paper research and have been synthesized by Integrated DNA technologies, engaging their special offer for iGEM teams. Before ordering, we used the IDT codon optimization tool to optimize the sequences for efficient expression in <i>E. coli</i>. Planning to submit the sequences to the registry, recognition sites for restriction enzymes used for standard cloning have been removed without causing amino acid changes. | ||
</br> | </br> | ||
− | + | The group of Prof. Dr. Michael Hust (TU Braunschweig) provided us with an <a href="http://parts.igem.org/Part:BBa_K1621006">antigen specific for <i>Salmonella</i> Typhimurium</a> and a <a href="http://parts.igem.org/Part:BBa_K1621007">corresponding single chain variable fragment (scFv)</a>. They generated the scFv themselves after identifying the immunodominant properties of the protein. Thanks to their work we are able to provide the registry with a specific pair of antigen and scFv. | |
</br> | </br> | ||
− | + | All our biobricks are summarized in the table below. Additionally, the table guides you to more detailed info pages as well as to the corresponding registry pages. | |
− | + | ||
− | + | ||
− | + | ||
</br> | </br> | ||
− | |||
− | |||
− | |||
− | |||
</br> | </br> | ||
+ | Although these parts significantly expand the registry in terms of diagnostics, none of them is our favorite biobrick. To reach the high yields of protein expression we needed for our project, we used a commercial vector optimized for inducible protein overexpression. This was unavoidable because inserting the required parts (like the lacI gene or a lacI repressible promoter) into pSB1C3 did not result in satisfying protein amounts. </br> | ||
+ | For improving a BioBrick, we developed a plasmid backbone that is adapted for efficient protein overexpression while fitting to iGEM standards. We wanted to enable every future iGEM team to perform highly efficient protein overexpression based on this backbone. Since working <i>in vitro</i> is an upcoming issue in synthetic biology, this is at once our favorite biobrick. <a href="">Find out more about the pOP vector </a>and see if it fits also your requirements! | ||
+ | </p> | ||
− | |||
− | |||
<div class="flexbox"> | <div class="flexbox"> | ||
<p> | <p> | ||
Line 64: | Line 58: | ||
</tr> | </tr> | ||
<tr class="row1"> | <tr class="row1"> | ||
− | <td class="col1"> <a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621009" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621009">BBa_K1621009</a></td><td class="col0"> Standardized plasmid backbone optimized for protein overexpression</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pOP-vector" title="pop_-_protein_expression_meets_igem_standards">pOP</a></td> |
</tr> | </tr> | ||
<tr class="row2"> | <tr class="row2"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621007" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621007">BBa_K1621007</a></td><td class="col0"> scFv binding specifically to the <i>Salmonella</i> Typhimurium derived antigen</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_13" title="prig15_13">pRIG15_13</a></td> |
</tr> | </tr> | ||
<tr class="row3"> | <tr class="row3"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621006" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621006">BBa_K1621006</a></td><td class="col0"><i> Salmonella</i> Typhimurium specific antigenic protein (DHAD)<td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_15" title="prig15_15">pRIG15_15</a></td> |
</tr> | </tr> | ||
<tr class="row4"> | <tr class="row4"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621005" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621005">BBa_K1621005</a></td><td class="col0"> <i> Treponema pallidum</i> specific antigenic peptides derived from bacterioferritin (TpF1)</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_18" title="prig15_18">pRIG15_18</a></td> |
</tr> | </tr> | ||
<tr class="row5"> | <tr class="row5"> | ||
Line 79: | Line 73: | ||
</tr> | </tr> | ||
<tr class="row6"> | <tr class="row6"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621003" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621003">BBa_K1621003</a></td><td class="col0"> <i> Clostridium tetani</i> specific antigenic epitopes derived from tetanus neurotoxin (TeNT_Hc)</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_11" title="prig15_11">pRIG15_11</a></td> |
</tr> | </tr> | ||
<tr class="row7"> | <tr class="row7"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621002" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621002">BBA_K1621002</a></td><td class="col0"> Herpes Simplex specific antigenic epitopes derived from glycoprotein G</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_8" title="prig15_8">pRIG15_8</a></td> |
</tr> | </tr> | ||
<tr class="row8"> | <tr class="row8"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621001" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621001">BBa_K1621001</a></td><td class="col0"> Varicella Zoster Virus specific antigenic epitopes derived from glycoprotein E</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_7" title="prig15_7">pRIG15_7</a></td> |
</tr> | </tr> | ||
<tr class="row9"> | <tr class="row9"> | ||
− | <td class="col1"><a class="urlextern" href="http://parts.igem.org/Part: | + | <td class="col1"> <a class="urlextern" href="http://parts.igem.org/Part:BBa_K1621000" rel="nofollow" target="_Blank" title="http://parts.igem.org/Part:BBa_K1621000">BBa_K1621000</a></td><td class="col0"> Rubella Virus specific antigenic epitopes derived from glycoprotein E1</td><td class="col0"><a class="wikilink1" href="https://2015.igem.org/Team:Freiburg/Project/pRIG15_6" title="pRIG15_6">pRIG15_6</a></td> |
</tr> | </tr> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
</table></div> | </table></div> | ||
Revision as of 19:45, 10 September 2015
Biobricks
Our project involved the expression of many antigenic peptides. Their immunodominant properties make them feasible for many medical purposes. As ‘Health and Medicine’ is one of the most popular tracks chosen by iGEM teams, we want to share the sequences encoding for these peptides with the iGEM community. Thus, future iGEM teams have the opportunity to take advantage from our research if they are planning to work in the field of diagnostics. Most of the sequences were obtained by paper research and have been synthesized by Integrated DNA technologies, engaging their special offer for iGEM teams. Before ordering, we used the IDT codon optimization tool to optimize the sequences for efficient expression in E. coli. Planning to submit the sequences to the registry, recognition sites for restriction enzymes used for standard cloning have been removed without causing amino acid changes. The group of Prof. Dr. Michael Hust (TU Braunschweig) provided us with an antigen specific for Salmonella Typhimurium and a corresponding single chain variable fragment (scFv). They generated the scFv themselves after identifying the immunodominant properties of the protein. Thanks to their work we are able to provide the registry with a specific pair of antigen and scFv. All our biobricks are summarized in the table below. Additionally, the table guides you to more detailed info pages as well as to the corresponding registry pages. Although these parts significantly expand the registry in terms of diagnostics, none of them is our favorite biobrick. To reach the high yields of protein expression we needed for our project, we used a commercial vector optimized for inducible protein overexpression. This was unavoidable because inserting the required parts (like the lacI gene or a lacI repressible promoter) into pSB1C3 did not result in satisfying protein amounts. For improving a BioBrick, we developed a plasmid backbone that is adapted for efficient protein overexpression while fitting to iGEM standards. We wanted to enable every future iGEM team to perform highly efficient protein overexpression based on this backbone. Since working in vitro is an upcoming issue in synthetic biology, this is at once our favorite biobrick. Find out more about the pOP vector and see if it fits also your requirements!
biobrick | short description | detailed desription |
---|---|---|
BBa_K1621009 | Standardized plasmid backbone optimized for protein overexpression | pOP |
BBa_K1621007 | scFv binding specifically to the Salmonella Typhimurium derived antigen | pRIG15_13 |
BBa_K1621006 | Salmonella Typhimurium specific antigenic protein (DHAD) | pRIG15_15 |
BBa_K1621005 | Treponema pallidum specific antigenic peptides derived from bacterioferritin (TpF1) | pRIG15_18 |
BBa_K1621004 | Human Immunodeficiency Virus specific antigenic epitopes derived from a polyprotein called gag/tat/pol/env | pRIG15_17 |
BBa_K1621003 | Clostridium tetani specific antigenic epitopes derived from tetanus neurotoxin (TeNT_Hc) | pRIG15_11 |
BBA_K1621002 | Herpes Simplex specific antigenic epitopes derived from glycoprotein G | pRIG15_8 |
BBa_K1621001 | Varicella Zoster Virus specific antigenic epitopes derived from glycoprotein E | pRIG15_7 |
BBa_K1621000 | Rubella Virus specific antigenic epitopes derived from glycoprotein E1 | pRIG15_6 |